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Abstnct: Our objective was to obtain new information on the in vitro antilymphocytic action of the 
cytokine synthesis inhibitor FK 506 and the punne biosynthesis inhibitors mycophcnolic acid (MPA; the 
active mOlctv of RS6l443) and mizoribine (MZB) when used alone or in combination. When added at 
the initiation of six·day human mixed lymphocyte cultures (MLC). FK 506. MPA or MZB exhibited 
dose·dependent inhibition 01 T·lymphocvtc DNA synthesis. FK 506. however. was «Xl· fold more potent 
than MPA. and ((}IXlO·fold more potent than MZB. Combination of FK 506 with either MPA or MZB. 
each at suboptlonal concentrations. produced no more than additive inhibitory effects on 'H thvmldine 
Incorporation. Two-colour !low cytometnc analvsls 01 Iymphocvtes revealed that none of the drugs 
affected cell surface activatIOn molecule expressIOn (CD25 = IL·2R 55 kD lJ·chain. HLA·DR or 
CD71 = transferrin receptor ITRJ) on allosllmulated CD4' or CD!!' cells harvested at three days 01 
culture. Bv day SIX. however. all three agents. at levels which markedly inhibited proliferation. 
suppressed the expression of activation markers on both CD4' and CD!!' cells. Also at day six. 
Inhibition 01 activation molecule expression on CD4' cells was achieved with the combination of FK 506 
and either MPA or MZB at concentrations which. on their own. were ineffective. These data provide 
new. additional informallon on the in vitro antilymphocytic action of FK 506. MPA and MZB when used 
alone and in combinallon. 
Introduction 
The ctticacy and clinical pOlential of a variety of new im· 
munosuppressive drugs when used alone or in combinallon 
are currently the subjects of critical evaluation. I.; The macro-
lide anlIbiotic FK 506 exhibits a similar molecular action to 
cyclosporin A (CsA)J and interferes with T cell proliferation 
sttmulated via the T cell receptor (TCR)lCD3 pathway. This 
dfect IS achieved by blocking of the transcription of genes 
encoding interleukin-2 (IL·2) and other cylokines.< FK 506 
has recently been shown to be effective in the prevention and 
rescue of human organ allograft rejection and may have a 
Address for correspondence: A W Thomson. Pillsburllh Transplant 
Instllute. Depanment of Surllery. W1544 Biomedical Science Tower. 
UniversllY 01' PitlsbuTllh. PiIlSbur!lh. PA 15213. USA. 
superior therapeutic index to CsA both in transplantal1on~ II 
and autoimmune disease," 
Mycophenolic acid (MPA; the active moiety of RS· 
() 1443 = mycophenolate mofetil) and mizoribine (MZR) are 
strong inhibitors of enzymes which catalyse the de novo 
synthesis of guanine nucleotides that arc essenlIal for T cell 
replication. They thus act later in the cell cycle than FK 506. 
By decreasing nucleotide availability. however. MPA and 
MZR may also inhibit signal transduction and the synthesis of 
cell surface proteins and receptors.II) .. 15 Both drugs have 
recently been shown to inhibit T cell responses in vitro.lb-IM In 
addition. MPA or MZR suppresses transplant rejection and 
each drug has been reported to act synergistically with CsA to 
prolong survival of experimental organ allografts. I .... 21 Moreo-
ver. MPA and MZR appear to be less toxic than azathioprine 
to the intestine and bone marrow. Thus. both MPA and MZR 
are of prospective clinical value as adjunctive immunosup-
pressive agents for use in combination with FK 506. 
Objectives 
To examine further the effects of FK 506. MP A and MZR 
on human T cell activation. we investigated the expression of 
several activation molecules (CD25 = IL-2R 55 kD a-chain. 
HLA-DR and C071 = transferrin receptor[TRJ) on allosti-
mulated CD4+ and CDS+ lymphocytes cultured in the pres-
ence of FK 506, MP A or MZR or when treated with 
combinations of FK 506 and either purine nucleotide synthe-
sis inhibitor. It was anticipated that the results obtained 
would provide additional. new information on the effect of 
these drugs on lymphocyte activation and assist in the design 
of drug combination therapies. 
Materials and methods 
FK 506 (Fujisawa Pharmaceutical Co. Osaka. Japan) and 
MPA (Sigma Chemical Co. St Louis. MO. USA) were 
dissolved initially in absolute ethanol. MZB (Asahi Chemical 
Industry Co Ltd. Tokyo. Japan) was dissolved in sterile. 
distilled water before further dilution in cell cuI lUre medium. 
Peripheral blood mononuclear cells were isolated over Ficoll-
Isopaque from heparinized samples obtained from healthy 
adult volunteers of both sexes. One-way mixed lymphocyte 
reaction (MLR) cultures were established in RPMI 1640. 
supplemented with 25 mmollL Hepes buffer and 100 Ulml 
gentamicin. with 10% normal human AB serum. Equal 
numbers (5 X 104 well) of responder and irradiated 
(2000 Rad) stimulator cells were set up in flat-bottomed 
micro titre plates in a total volume of 0.2 ml. Cells were 
cultured for three or six days. [-'H)-thymidine (I f.l.Ci/welll 
was added for the final 16 hours of culture. The cells were 
harvested onto glass fibre discs. ustng a multiple harvester and 
['HI-thymidine uptake was estimated using a 1205 Betaplate 
liquid scintillation counter (Pharmacla LKB Biotechnology 
Inc .. Piscataway. NJ). Results are expressed as mean counts 
per mmute (cpm). 
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Cultured mononuclear cells were washed and the expres-
sion of activation antigens was detected as described pre-
viously24 by staining cells with mC-conjugated anti-C025 
(IL-2 receptor. a chain). anti-HLA-DR or anti-CD71 (TR) 
mouse IgG monoclonal antibodies and either phycoerythrin 
(PE)-conjugated anti-C04 or anti-CDS mouse monoclonal 
antibodies. All antibodies were from DAKO and were used 
at a final I : 10 dilution. mc- and PE-conjugated mouse IgO 
were used as background control. After washing, cells were 
fixed with 1 % wlv paraformaldehyde. followed by analysis in 
a FACSTAR flow cytometer (Becton-Dickinson, Rariton. 
NJ, USA). Five thousand cells were counted for each sample. 
Significances of differences between means were determined 
using Student's t-test. 
Results 
The influence of various concentrations of FK 506, MP A or 
MZB. added at the start of culture. on the uptake JH-TdR in 
six-day human MLC is shown in Figure I. Each drug ex-
hibited a dose-related. inhibitory effect with maximal inhibi-
tion of DNA synthesis (85-97%) being achieved with 1.2 nM 
FK 506.0.3 f.l.M MPA and 386 f.l.M MZB. Combinations of 
moderately effective concentrations of FK 506 and either 
MPA or MZB produced no more than an additive inhibitory 
dfect on cell proliferation. 
The effects of thc three immunosuppressive agents on 
human T cell surface IL-2R. HLA-DR and TR expression in 
three- and six-day MLC were examined by two-colour flow 
cytometric analysis. Cultures harvested after three days in the 
presence of FK 506. MPA or MZB showed no significant 
change in the incidence of CD4 + or CaU~ cells co-expressing 
any of the activation markers (data not shown). By day six. 
however. there were significant inhibitory effects of all three 
drugs on the incidence of both CD4' and CD8+ cells co-
<.!xpressing each of the markers (Figure 2). At concentrations 
()f each drug which gave maXimal inhibition of DNA syntheSIS 
(Figure I). but not at tenfold lower concentrations (which 
were moderately antiproliferativel. FK 506. MPA and MZR 
significantly inhibited (p < (1.025) expressIOn of IL-2R on both 
CD4' and COil' cells. The extcnt of supprcssion ER~F%F 
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DRUG CONCENTRATION 
f1pre 1 The inftuence of vanous concentrallons ot FK 506. MPA and MZB and of drull 
combinallon on human MLR. Uptake of ·'HTdR was quantitated over the lasl 16 hours of 
six-day cultures. Results are means::!: I SO oblained (rom three separale expenments. 
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F'tpft 2 The incidence of CD4· and CDS' lymphocytes expressing IL·2R. HLA·DR or TR 
in (A) FK 506-treated: (8) MPA·treated: and (C) MZB·treated MLC determmed by two· 
colour tlow cytometnc analysis six days after establishment of cultures. Rcsults are 
means :: 1 SO obtained from three separate expenments. 
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Figure 3 The incidence of CD4 + and CD8+ lymphocytes expressing IL-2R. HLA-DR or TR 
in six-day MLC cultures treated witn concentrations of FK 506 and MZB whicn. on their 
own. did not affect tne expression of these markers. Results are means = 1 SO obtained 
from three separate expenments. MZB 110M; FK 506 nM. 
was similar for both T cell subsets. although MZB was 
especially effective in suppressing CD8+ IL-2R expression 
(>80%). MZR was also the most effective agent and both 
MZR and MPA more effective than FK 506 in suppressing 
HLA-DR expression. Differences between the effects of 
these drugs. however. were not stastically significant. The 
incidence of CD4 + and CD8 + cells expressing TR was also 
inhibited (p < 0.02) by all three drugs and to a greater extent 
than IL-2R and HLA-DR. although as with the latter activa-
tion markers. at only the highest drug concentration tested. 
Combinations of FK 506 and either MPA or MZB at 
concentraUons which. on their own caused only moderate 
Inhibition of DNA synthesis and no significant reducuon In 
cell surface marker expression. reduced the incidence of IL-
2R·. HLA-DR'. and TR· cd Is (Figure J; data shown for 
FK 506-MZB combination only). 
Discussion 
In this study. we have shown that the immunosuppressive 
agents. FK 506. MPA (the active moiety of RS-61443) and 
MZB each has the capacity to profoundly inhibit T cell 
proliferatlon and the expression of T cell surface activation 
molecules following allostimulauon. In each instance. sig-
mfican! suppression of IL-2R (CD25; 55 kD a-chain). HLA-
DR and TR (CD71) on CD4' and CDS' cells was observed 
at six but not at three days of culture. Moreover. this effect 
was achieved at drug concentrations which caused at least 
XO% inhibition of cell proliferation: lower concentrations. 
which produced <70% inhibition of DNA synthesis. did not 
suppress actlvation marker expression. 
Despite these similarities in the effects of the three agents. 
marked differences In potency were recorded. FK 506 proved 
highly effective in inhibiting cell proliferation at approx-
imately I nM. whilse MPA and MZB were 100- and 
IOOOO-foid less potent. Our data also confirm the distinct 
modes of action of FK 506 on the one hand and MPA and 
MZB on the other. FK 506 has been shown to inhtbit 
selectively the activation and proliferation of T cells stimu-
lated via the T cell receptor/CD3 pathway:·O~KOS Following 
binding of FK 506 to its intracellular. cytosolic receptor 
FK 506 binding protein (FKBP: predominant member FKBP-
12). the FK 506-FKBP-complex binds to the calcium-
activated phosphatase calcineurin.27 Current thinking is that 
FK 506 may block dephosphorylation of the cytosolic compo-
nent of the nuclear factor of activated T cells (NFAT)2H that is 
required for transcription of IL-2 mRNA. 
Here we have extended our previous observations24•29 that 
FK 506 inhibits activation molecule expression on OKT3 
stimulated or alloactivated human Iymphocvtes. Thus. in the 
present study. using two-colour immunoftuorescence staining. 
we have shown that FK 506 inhibits lL-2R. HLA-DR and TR 
on both CD4 + and CD8' alloactivated T cells. We could not 
confirm an earlier report by Kino el alK"~ that FK 506 inhibited 
IL-2R (CD25) more markedly on CDH' than on alloactivated 
CD4+ cells. 
The antiproliferative effects of MFA and MZB differ 
distinctly from those of FK 506. Both former drugs are purine 
biosynthesis inhibitors. It has been reported that Immunosup-
pressive doses of MPA do not deplete lymphocytes and may 
have no effect on DNA synthesis In nonlymphoid tissues. 
such as gut epithelium or on most bone marrow progenitor 
cells.'" We have observed that neither MPA nor MZB affects 
Con A-induced T cell cvtokine gene expressIOn ([L-2. IL-4. 
IFN-"/ or lL-IO) (data not shown). Little previous data arc 
available concermng the effects of MPA or MZB on cyto-
kines. Turka III al. l ? however. recently reported failure of 
MZB to inhibit phorbol mynstate acetate 
(PMA) + ionomycin-induced human T celllL-2 gene expres-
sion or cell surface 55 kD IL-2R expressIOn. In the latter 
instance. the anugen was studied after T cells were stimulated 
with PMA + ionomycin + antl-CD28. a much more powerful 
stimulus than the alloantigen used in the present study. This 
difference In strength of stimulus may explain the apparent 
discrepancy between the two studies. 
Advances in our understanding of events underlying T cell 
activation have helped pmpomt slles of actlon of immunosup-
pressive drugs and aided in the design of new drug combina-
tion therapies. [n this study. combination of a suboptimal 
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concentration of FK 506 with either MP A or MZB was found 
to inhibit cell proliferation at approximately the level seen 
with tenfold higher concentrations of FK 506. The apparent 
selectively of MP A and MZB for lymphoid T cells in vivo 
suggests that use of FK 506 together with either MP A or 
MZB may be useful for the immunosuppressive therapy of 
human allograft rejection. Indeed. Sollinger et al.21 reported 
recently on the efficacy and safety of MPA (RS-61443) in 
combination with low doses of CsA and prednisone in clinical 
renal transplantation. Furthermore. like FK 506. neither 
MP A nor MZB has been reported to affect the bone marrow 
at immunosuppressive doses.16.1 7 a possible advantage over 
azathioprine in minimizing the toxicity of drug combination 
therapy. 
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